Phage therapy for Clostridium difficile infection: An alternative to antibiotics?

Seminars in Colon and Rectal Surgery

Volumn 25, Issue 3, 2014, Pages 167-170

  Sangster, William ^a   Hegarty, John P ^a   Stewart, David B ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PHAGE TALE LIKE PARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CLEARANCE; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; HUMAN; INFECTION CONTROL; INTESTINE FLORA; INTESTINE INFECTION; MOLECULAR THERAPY; MYOVIRIDAE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; SIPHOVIRIDAE; VIRUS GENE; VIRUS LIKE AGENT; VIRUS REPLICATION;

EID: 84926206109     PISSN: 10431489     EISSN: 15584585     Source Type: Journal    
DOI: 10.1053/j.scrs.2014.05.014     Document Type: Article

References (35)

1. Twort F.W. An investigation on the nature of the ultra-microscopic viruses. Lancet 1915, 186(4814):1241-1243.
2. d'Herelle F. Sur un microbe invisible antagoniste des bacilles dysenteriques. CR Acad Sci 1917, 165:373-375.
3. Summers WC. Phage and the early development of molecular biology, In: Abedon ST, Calendar RL eds. The Bacteriophages. Oxford University Press; 2005. 3-7.
4. Ackermann HW. Classification of bacteriophages, In: Abedon ST, Calendar RL eds. The Bacteriophages. Oxford University Press, 2005. 8-16.
5. Leuven: Virus taxonomy. 2012 release. International Committee on Taxonomy of Viruses, July 2012. Web November 2013.
6. Ackermann H.W. Tailed bacteriophages the order caudovirales. Adv Virus Res 1998, 51:135-201.
7. Fortier L.C., Moineau S. Morphological and genetic diversity of temperate phages in Clostridium difficile. Appl Environ Microbiol 2007, 73(22):7358-7366.
8. Nale J.Y., Shan J., Hickenbotham P.T., et al. Diverse temperate bacteriophage carriage in Clostridium difficile 027 strains. PLoS One 2012, 7(5):e37263.
9. Brüssow H., Hendrix R.W. Phage genomics: small is beautiful. Cell 2002, 108(1):13-16.
10. Fortier L.C., Sekulovic O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 2013, 4(5):354-365.
11. Samson J.E., Magadán A.H., Sabri M., et al. Revenge of the phages: defeating bacterial defences. Nat Rev Microbiol 2013, 11(10):675-687.
12. Yacoby I., Shamis M., Bar H., et al. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob Agents Chemother 2006, 50(6):2087-2097.
13. Echols H. Developmental pathways for the temperate phage: lysis vs lysogeny. Annu Rev Genet 1972, 6(0):157-190.
14. Ferguson S., Roberts C., Handy E., et al. Lytic bacteriophages reduce Escherichia coli O157: H7 on fresh cut lettuce introduced through cross-contamination. Bacteriophage 2013, 3(1):e24323.
15. Woolston J., Parks A.R., Abuladze T., et al. Bacteriophages lytic for Salmonella rapidly reduce Salmonella contamination on glass and stainless steel surfaces. Bacteriophage 2013, 3(3):e25697.
16. El-Arabi T.F., Griffiths M.W., She Y.M., et al. Genome sequence and analysis of a broad-host range lytic bacteriophage that infects the Bacillus cereus group. Virol J 2013, 10(48):10-48.
17. Brüssow H. Prophage genomics. The Bacteriophages 2005, 17-23. Oxford University Press. S.T. Abedon, R.L. Calendar (Eds.).
18. Ohnishi M., Kurokawa K., Hayashi T. Diversification of Escherichia coli genomes: are bacteriophages the major contributors?. Trends Microbiol 2001, 9(10):481-485.
19. Herold S., Karch H., Schmidt H. Shiga toxin-encoding bacteriophages: genomes in motion. Int J Med Microbiol 2004, 294(2-3):115-121.
20. Yoshizawa Y., Sakurada J., Sakurai S., et al. An exfoliative toxin A-converting phage isolated from Staphylococcus aureus strain ZM. Microbiol Immunol 2000, 44(3):189-191.
21. Spellberg B., Powers J.H., Brass E.P., et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004, 38(9):1279-1286.
22. Canton R., Morosini M.I. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol 2011, 35(5):977-991.
23. Round J.L., Mazmanian S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009, 9(5):313-323.
24. Skraban J., Dzeroski S., Zenko B., et al. Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes. PLoS One 2013, 8(2):e58005.
25. Merril C.R., Scholl D., Adhya S. Phage therapy. The Bacteriophages 2005, 725-741. Oxford University Press. S.T. Abedon, R.L. Calendar (Eds.).
26. Drulis-Kawa Z., Majkowska-Skrobek G., Maciejewska B., et al. Learning from bacteriophages-advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci 2012, 13(8):699-722.
27. Merril C.R., Biswas B., Carlton R., et al. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 1996, 93:3188-3192.
28. Shan J., Patel K.V., Hickenbotham P.T., et al. Prophage carriage and diversity within clinically relevant strains of Clostridium difficile. Appl Environ Microbiol 2012, 78(17):6027-6034.
29. Meader E., Mayer M.J., Gasson M.J., et al. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 2010, 16(6):549-554.
30. Meader E., Mayer M.J., Steverding D., et al. Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 2013, 22:25-30.
31. Schmelcher M., Donovan D.M., Loessner M.J. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 2012, 7(10):1-25.
32. Mayer M.J., Narbad A., Gasson M.J. Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol 2008, 190(2):6734-6740.
33. Michel-Briand Y., Baysse C. The pyocins of Pseudomonas aeruginosa. Biochimie 2002, 84(5-6):499-510.
34. Gebhart D., Williams S.R., Bishop-Lilly K.A., et al. Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile. J Bacteriol 2012, 194(22):6240-6247.
35. Nakayama K., Takashima K., Ishihara H., et al. The R-type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F-type is related to lambda phage. Mol Microbiol 2000, 38(2):213-231.